Abstract
In spite of 35 years of experience with antipsychotic drugs, the psychiatrists are still faced with the limitations of these drugs: no or minimal therapeutic effect in hallucinations and delusions in about 25% of schizophrenic patients; persisting anergia and emotional withdrawal in otherwise successfully treated patients; a great spectrum of side effects, some irreversible. Quo vadis? An incidental discovery of a completely new drug, a new “chlorpromazine” would be the ideal solution, but for the present, one has to continue with the small pragmatic steps, especially within the following areas: (a) the selective antidopaminergic drugs, especially the substituted benzamides, may be further developed in the direction of antipsychotic selectivity with fewer and fewer extrapyramidal side effects; (b) the atypical clozapine ought soon to have successors, hopefully without the risk of bone marrow depression and cardiovascular side effects; (c) the D1 antagonists as well as the D1 agonists may imply therapeutically valuable effects; (d) the dopamine autoreceptor has long been in focus, but until now, no pure agonist has been found, and the drugs available, including (−)3-PPP, appear to have many side effects; (e) serotonin antagonists may be an interesting possibility; and (f) when it may be possible to influence brain peptides more efficiently than up to now, this area will probably provide us with several psychotropic drugs. Furthermore, during the search for new antipsychotic drugs, one must not forget to improve the practical use of available neuroleptics and of nonpharmacological, psychosocial treatment modalities.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Angst J, Haenicke U, Padrutt A (1971) Ergebnisse eines Doppelblind-Versuches von HF-1854(8-chlor-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e)(l,4)diazepine) im Vergleich zu Levomepromazin. Pharmakopsychiatr Neuropsychopharmakol 4: 192–200
Arnt J, Hyttel (1986) Inhibition of SKF 38393- and pergolide-induced circling in rats with unilateral 6-OHDA lesion is correlated to dopamine D-l and D-2 receptor affinities in vitro. J Neural Transm 67: 225–240
Bürki HR, Sayers AC, Ruch W, Asper H (1977) Effects of clozapine and other dibenzo-epines on central dopaminergic and cholinergic systems. Arzneimittelforsch 27: 1561–1565
Carlsson A (1985) Pharmacological properties of presynaptic dopamine receptor agonists. In: Casey DE, Chase TN, Christensen AV, Gerlach J (eds) Dyskinesia. Research and treatment. Springer, Berlin Heidelberg New York, pp 31–38
Christensen AV, Arnt J, Svendsen O (1985) Pharmacological differentiation of dopamine D-l and D-2 antagonists after single and repeated administration. In: Casey DE, Chase TN, Christensen AV, Gerlach J (eds) Dyskinesia. Research and treatment. Springer, Berlin Heidelberg New York, pp 182–190
DeLisi LE, Neckers LM, Weinberger DR, Wyatt RJ (1981) Increased whole blood serotonin concentrations in chronic schizophrenic patients. Arch Gen Psychiatry 38: 647–650
Gerlach J, Koppelhus P, Helweg E, Monrad A (1974) Clozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiatr Scand 50: 410–424
Gerlach J, Thorsen K, Fog R (1975) Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients. Psycho- pharmacologia (Berlin) 40: 341–350
Gerlach J, Behnke K, Heltberg J, Munk-Andersen E, Nielsen H (1985) Sulpiride and haloperidol in schizophrenia: a double-blind cross-over study of therapeutic effect, side effects and plasma concentrations. Br J Psychiatry 147: 283–288
Gerlach J, Casey DE, Korsgaard S (1986) Tardive dyskinesia: epidemiology, pathophysiology, and pharmacology. In: Shah NS, Donald AG (eds) Movement disorders. Plenum, New York, pp 119–147
Gerlach J, Kistrup K, Korsgaard S (1987) Effect of selective D-l and D-2 dopamine receptor antagonists and agonists in cebus monkeys: implications for acute and tardive dyskinesias. In: Dahl SG, Gram LF, Paul SM, Potter WZ (eds) Clinical pharmacology in psychiatry. Selectivity in psychotropic drug action — promises or problems? Springer, Berlin Heidelberg New York, pp 236–247
Häggström JE, Günne LM, Carlsson A, Wikström H (1983) Antidyskinetic action of 3-PPP, a selective dopaminergic autoreceptor agonist, in cebus monkeys with persistent neuroleptic-in- duced dyskinesias. J Neural Transm 58: 135–142
Hartvig P, Eckernäs SÅ, Lindström L, Ekblom B, Bondesson U, Lundqvist H, Halldin C, Nägren K, Längström B (1986) Receptor binding of N-(methyl-11C) clozapine in the brain of rhesus monkey studied by positron emission tomography ( PET ). Psychopharmacology (Berlin) 89: 248–252
Hyttel J, Larsen J J, Christensen AV, Arnt J (1985) Receptor-binding profiles of neuroleptics. In: Casey DE, Chase TN, Christensen AV, Gerlach J (eds) Dyskinesia. Research and treatment. Springer, Berlin Heidelberg New York, pp 9–18
Jenner P, Rupniak NMJ, Marsden CD (1985) Differential alteration of striatal D-l and D-2 receptors induced by the long-term administration of haloperidol, sulpiride or clozapine to rats. In: Casey DE, Chase TN, Christensen AV, Gerlach J (eds) Dyskinesia. Research and treatment: Springer, Berlin Heidelberg New York, pp 174–181
Kalakowska T, Gadhvi H, Molyneux S (1987) An open clinical trial of fenfluramine in chronic schizophrenia: a pilot study. Int Clin Psychopharmacol 2: 83–88
Krupp P, Monka C (1982) Agranulocytosis during Leponex treatment. Situation report, March 31,1982. Sandoz document
Ögren SO, Hall H, Köhler C, Magnusson O, Sjöstrand S-E (1986) The selective dopamine D-2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions. Psychopharmacology (Berlin) 90: 287–292
Pakkenberg H, Pakkenberg B (1986) Clozapine in the treatment of tremor. Acta Neurol Scand 73: 295–297
Robertson A, MacDonald C (1984) Atypical neuroleptics clozapine and thioridazine enhance amphetamine-induced stereotypy. Pharmacol Biochem Behav 21: 97–101
Sedvall G (1984) The use of substituted benzamides in psychiatry. Acta Psychiatr Scand [Suppl] 69: 1–162
Sedvall G, Bjerkenstedt L, Lindström L, Wode-Helgodt B (1978) Clinical assessment of dopamine receptor blockade. Life Sci 23: 425–430
Tamminga CA, Littman RL, Alphs Ld, Chase TN, Thaker GK, Wagman AM (1986) Neuronal cholecystokinin and schizophrenia: pathogenic and therapeutic studies. Psychopharmacology (Berlin) 88: 387–391
Waddington JL (1986) Behavioral correlates of the action of selective D-l dopamine receptor antagonists. Biochem Pharmacol 35: 3661–3667
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Gerlach, J. (1988). Future Treatment of Schizophrenia. In: Casey, D.E., Christensen, A.V. (eds) Psychopharmacology: Current Trends. Psychopharmacology Series, vol 5. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73280-5_8
Download citation
DOI: https://doi.org/10.1007/978-3-642-73280-5_8
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-73282-9
Online ISBN: 978-3-642-73280-5
eBook Packages: Springer Book Archive